No, the yellow material in that carotid artery is not CRP. It is atherosclerotic plaque, specifically the lipid-rich necrotic core and atheroma that has built up inside the carotid artery.

During a carotid endarterectomy, the surgeon opens the carotid artery and removes the plaque that is narrowing the vessel.

What is in that yellow plaque?

Mainly:

1. Cholesterol-containing lipids

• Cholesterol esters

• Free cholesterol

• Oxidized lipids

These lipids largely arrive because ApoB-containing particles (LDL, VLDL remnants, Lp(a), etc.) entered the artery wall and became trapped.

ApoB is basically the "delivery vehicle" — every ApoB particle carries one atherogenic particle into the arterial wall.

Also present:

2. Immune cellsEspecially:

• macrophages

• T cells

Macrophages eat modified LDL particles and become foam cells (fat-filled immune cells).

That creates the yellow appearance.

Where does hs-CRP fit in?

CRP is not a physical component you see as yellow gunk.

hs-CRP is a blood marker produced mainly by the liver in response to inflammatory signaling (especially IL-6). It reflects the inflammatory state associated with:

• macrophage activation

• cytokine signaling

• endothelial dysfunction

• plaque instability

Inside the plaque you may find inflammatory proteins and immune signaling, but you would not look at the plaque and say:

"that yellow stuff is CRP."

A simplified way to visualize it:

ApoB particles = the cholesterol cargo trucks entering the artery wall 🚚Plaque = the accumulated cargo + immune response + scar tissue 🧱hs-CRP = a blood signal that inflammation around this process is elevated 🔥

This is why ApoB is considered upstream for plaque formation, while hs-CRP helps identify how inflamed and potentially unstable the vascular environment is.

Can you create plaque even with a perfect CRP and insulin?

Yes. A person can develop carotid atherosclerosis with elevated ApoB as the primary abnormality even if hs-CRP is low and insulin sensitivity is excellent.

This is actually one of the most important concepts in modern lipidology: atherosclerosis does not require metabolic syndrome or systemic inflammation to begin.

The core causal pathway looks like this:

↑ ApoB-containing particles → arterial wall retention → immune response → plaque formation

The first step can happen before you ever see elevated hs-CRP.

Why ApoB alone can drive plaque

ApoB particles (LDL, remnant particles, Lp(a), IDL) circulate in the blood. Because of their size and biology, they can enter the artery wall through the endothelium.

Once trapped:

1. ApoB particles bind to arterial proteoglycans

2. They become modified (oxidized, glycated, aggregated)

3. Immune cells recognize them

4. Macrophages ingest them → foam cells

5. Fatty streak → fibrous plaque → calcification/remodeling

The immune system gets involved because of the retained particles, not necessarily because someone already has a high systemic inflammatory marker.

Evidence that ApoB can be harmful independent of inflammation/metabolism

Familial hypercholesterolemia (FH) is the clearest example.

Many FH patients have:

• very high ApoB exposure from birth

• normal insulin sensitivity

• normal triglycerides

• sometimes normal hs-CRP

Yet they develop:

• carotid plaque

• coronary disease

• premature MI

The common denominator is lifelong ApoB particle exposure.

What about people with low CRP?

Low hs-CRP means:

"There is less measurable systemic inflammatory signaling."

It does not mean:

"There is no inflammation in the artery wall."

Atherosclerosis is a localized inflammatory process. Blood markers can miss what is happening inside the vessel.

A person could have:

Marker	Result
ApoB	High
hs-CRP	Low
fasting insulin	Low
A1c	Normal
triglycerides	Low

…and still accumulate plaque over decades.

Where insulin resistance changes the picture

Insulin resistance accelerates the process because it tends to cause:

• higher VLDL/remnant production

• higher triglycerides

• smaller LDL particles

• endothelial dysfunction

• inflammatory signaling

So insulin resistance is a risk amplifier, but it is not a requirement.

A useful analogy:

• ApoB is the amount of material being deposited

• insulin resistance is an environment that increases deposition and damage

• hs-CRP is a signal that inflammatory activity is elevated

You can build plaque with the first alone.

This is why trials lowering ApoB-containing particles (statins, ezetimibe, PCSK9 inhibitors, etc.) reduce plaque and heart attacks and strokes.